This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Rhabdomyolysis and Coma Associated With Amisulpride: A Probable Atypical Presentation of Neuroleptic Malignant Syndrome

E. Cem Atbasoglu, MD; Halise Devrimci Ozguven, MD; Meram Can Saka, MD; Ceren Goker, MD;

Published: December 15, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The limitations of the current medications used to treat schizophrenia have led to a search for adjunctive treatments that may better address the negative symptoms, cognitive deficits, and behavioral problems of the disorder. A promising strategy might be adopted from the current use of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease.1 Acetylcholinesterase inhibitors (e.g., tacrine, donepezil) improve general cognitive functioning and reduce apathy, anxiety, agitation, and other psychiatric symptoms in Alzheimer’s patients.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Neuroleptic Malignant Syndrome , Side Effects-Medication

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...